Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04026412
Recruitment Status : Recruiting
First Posted : July 19, 2019
Last Update Posted : May 24, 2022
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer (NSCLC) Biological: nivolumab Biological: ipilimumab Biological: durvalumab Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 888 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
Actual Study Start Date : October 8, 2019
Estimated Primary Completion Date : July 7, 2025
Estimated Study Completion Date : December 3, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm A: nivolumab + CCRT + ipilimumab
Concurrent chemoradiotherapy (CCRT)
 Biological: nivolumab
Specified dose on specified days

Biological: ipilimumab
Specified dose on specified days
Experimental: Arm B: nivolumab + CCRT
Concurrent chemoradiotherapy (CCRT)
 Biological: nivolumab
Specified dose on specified days
Experimental: Arm C: CCRT + durvalumab
Concurrent chemoradiotherapy (CCRT)
 Biological: durvalumab
Specified dose on specified days


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Progression-free survival (PFS) by RECIST 1.1 per Blinded Independent Central Review (BICR) for Arm A vs Arm C [ Time Frame: Up to 7 years ]

Secondary Outcome Measures :
  1. Overall Survival (OS) for Arm A vs Arm C [ Time Frame: Up to 7 years ]
  2. PFS by RECIST 1.1 per BICR for Arm B vs Arm C [ Time Frame: Up to 7 years ]
  3. OS for Arm B vs Arm C [ Time Frame: Up to 7 years ]
  4. PFS by RECIST 1.1 per BICR for Arm A vs Arm B [ Time Frame: Up to 7 years ]
  5. OS for Arm A vs Arm B [ Time Frame: Up to 7 years ]
  6. Objective Response Rate (ORR) by RECIST 1.1 per BICR [ Time Frame: Up to 7 years ]
  7. Duration of Response (DoR) by RECIST 1.1 per BICR [ Time Frame: Up to 7 years ]
  8. Time to Response (TTR) by RECIST 1.1 per BICR [ Time Frame: Up to 7 years ]
  9. PFS by RECIST 1.1 per Investigator assessment [ Time Frame: Up to 7 years ]
  10. ORR by RECIST 1.1 per Investigator assessment [ Time Frame: Up to 7 years ]
  11. DoR by RECIST 1.1 per Investigator assessment [ Time Frame: Up to 7 years ]
  12. TTR by RECIST 1.1 per Investigator assessment [ Time Frame: Up to 7 years ]
  13. Time to Death or Distant Metastases (TTDM) by RECIST 1.1 per Investigator assessment [ Time Frame: Up to 7 years ]
  14. Incidence of Adverse Events (AEs) [ Time Frame: Up to 7 years ]
  15. Incidence of Serious Adverse Events (SAEs) [ Time Frame: Up to 7 years ]
  16. Incidence of select AEs [ Time Frame: Up to 7 years ]
  17. Proportion of participants without symptom deterioration based on NSCLC-SAQ [ Time Frame: Up to 7 years ]
    Non-Small Cell Lung Cancer-Symptom Assessment Questionnaire (NSCLC-SAQ)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  • Locally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) pathologically-confirmed NSCLC, according to 8th TNM classification. Participants who are not planned for potential curative surgical resection are eligible.
  • Newly diagnosed and treatment-naïve, with no prior local or systemic anticancer therapy given as primary therapy for locally advanced disease

Exclusion Criteria:

  • Any condition including medical, emotional, psychiatric, or logistical that, in the opinion of the Investigator would preclude the participant from adhering to the protocol or would increase the risk associated with study participation
  • Active infection requiring systemic therapy within 14 days prior to randomization
  • History of organ or tissue transplant that requires systemic use of immune suppressive agents
  • Prior thoracic radiotherapy

Other protocol-defined inclusion/exclusion criteria apply

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04026412


Contacts
Layout table for location contacts
Contact: BMS Study Connect Contact Center http://www.bmsstudyconnect.com 855-907-3286 Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #.

Locations
Show Show 196 study locations
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT04026412    
Other Study ID Numbers: CA209-73L
2019-001222-98 ( EudraCT Number )
First Posted: July 19, 2019    Key Record Dates
Last Update Posted: May 24, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
 Bronchial Neoplasms
Nivolumab
Ipilimumab
Durvalumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action